Literature DB >> 15343145

Suspension of rotavirus vaccine after reports of intussusception--United States, 1999.

.   

Abstract

On July 16, 1999, CDC recommended that health-care providers suspend use of the licensed rhesus-human rotavirus reassortant-tetravalent vaccine (RRV-TV) (RotaShield, Wyeth Laboratories, Inc., Marietta, Pennsylvania) in response to 15 cases of intussusception (i.e., a bowel obstruction in which one segment of bowel becomes enfolded within another segment) among infants who received RRV-TV. The Vaccine Adverse Event Reporting System (VAERS) monitored for adverse events following licensure of RRV-TV on August 31, 1999. After the recommendation to suspend use of the vaccine, no additional cases were reported. This report describes the surveillance activities used to identify this vaccine adverse event, the emergency response, and follow-up investigations. Suspension of RRV-TV after the initial cases of intussusception parallels the removal of the Broad Street pump handle in response to John Snow's epidemiologic studies; both were decisive, life-saving public health actions.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15343145

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  13 in total

Review 1.  Deaths following vaccination: What does the evidence show?

Authors:  Elaine R Miller; Pedro L Moro; Maria Cano; Tom T Shimabukuro
Journal:  Vaccine       Date:  2015-05-23       Impact factor: 3.641

2.  Rotavirus vaccine and intussusception.

Authors:  Stephan Foster
Journal:  J Pediatr Pharmacol Ther       Date:  2007-01

3.  Genotypic characterization of canine coronaviruses associated with fatal canine neonatal enteritis in the United States.

Authors:  Beth N Licitra; Gary R Whittaker; Edward J Dubovi; Gerald E Duhamel
Journal:  J Clin Microbiol       Date:  2014-09-24       Impact factor: 5.948

4.  The association between intentional delay of vaccine administration and timely childhood vaccination coverage.

Authors:  Philip J Smith; Sharon G Humiston; Trish Parnell; Kirsten S Vannice; Daniel A Salmon
Journal:  Public Health Rep       Date:  2010 Jul-Aug       Impact factor: 2.792

Review 5.  Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS).

Authors:  Tom T Shimabukuro; Michael Nguyen; David Martin; Frank DeStefano
Journal:  Vaccine       Date:  2015-07-22       Impact factor: 3.641

6.  The Immunologic Complexity of Growing Up with Malaria--Is Scientific Understanding Coming of Age?

Authors:  Matthew B Laurens
Journal:  Clin Vaccine Immunol       Date:  2015-12-16

7.  Safety and Immunogenicity of Sequential Rotavirus Vaccine Schedules.

Authors:  Romina Libster; Monica McNeal; Emmanuel B Walter; Andi L Shane; Patricia Winokur; Gretchen Cress; Andrea A Berry; Karen L Kotloff; Kwabena Sarpong; Christine B Turley; Christopher J Harrison; Barbara A Pahud; Jyothi Marbin; John Dunn; Jill El-Khorazaty; Jill Barrett; Kathryn M Edwards
Journal:  Pediatrics       Date:  2016-01-28       Impact factor: 7.124

Review 8.  The first rotavirus vaccine and the politics of acceptable risk.

Authors:  Jason L Schwartz
Journal:  Milbank Q       Date:  2012-06       Impact factor: 4.911

Review 9.  Data mining in the US using the Vaccine Adverse Event Reporting System.

Authors:  John Iskander; Vitali Pool; Weigong Zhou; Roseanne English-Bullard
Journal:  Drug Saf       Date:  2006       Impact factor: 5.228

10.  A qualitative assessment of factors influencing acceptance of a new rotavirus vaccine among health care providers and consumers.

Authors:  Manish M Patel; Alan P Janssen; Richard R Tardif; Mark Herring; Umesh D Parashar
Journal:  BMC Pediatr       Date:  2007-10-18       Impact factor: 2.125

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.